Search clinical trials for: Chronic obstructive pulmonary disease, indacaterol, tiotropium, placebo controlled

Total 100577 results

Altesa Biosciences, Inc.
Virtus Respiratory Research

Recruiting

RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection

Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | Enterovirus Infections | Copd | Pulmonary Disease | Respiratory Disease | Respiratory Complication | Upper Respiratory Tract Infections | Respiratory Viral Infection | ... and other conditions

United Kingdom
Capital Medical University
Peking University; Guang'anmen Hospital of China Academy of Chinese Medical... and other collaborators

Not yet recruiting

Treatment Efficacy of Systemic Corticosteroids in AECOPD Patients With Higher Blood Eosinophil Levels

Lung Diseases, Obstructive | Pulmonary Disease, Chronic Obstructive | COPD | Morality | Acute Exacerbation of COPD | Corticosteroid | Blood Eosinophil Count
Henan University of Traditional Chinese Medicine

Recruiting

Effects of Traditional Chinese Medicine on Outcomes in Patients With AECOPD Risk Window

Chronic Obstructive Pulmonary Disease

China
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Argentina, Austria, Bosnia and Herzegovina, Chile, Croatia, Czechia, Estonia, Germany, Greece, Hungary, Israel, Latvia, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian Federation and more
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) (PILASTER)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Albania, Argentina, Australia, Austria, Bosnia and Herzegovina, Chile, China, Czechia, Georgia, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian... and more
Prof. Dr. Jörg Leuppi
Kantonsspital Baselland Bruderholz; Institut für Hausarztmedizin Basel

Recruiting

Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD (RECUT)

Pulmonary Disease, Chronic Obstructive | Disease Exacerbation | Adverse Effect of Glucocorticoids and Synthetic Analogues

Switzerland
AstraZeneca

Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis (FRONTIER-4)

Chronic Obstructive Pulmonary Disease (COPD) | Chronic Bronchitis

United States, Canada, Denmark, Spain, United Kingdom, Taiwan, New Zealand, Australia, Germany, Israel, South Africa, Czechia, Hungary, Poland, Netherlands
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD (BECOMEG)

Pulmonary Disease | Chronic Obstructive (MeSH)

France
University of Leicester
Genentech, Inc.; Biomedical Research Centre- Respiratory (Glenfield Hospital...

Completed

Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) (COPD-ST2OP)

COPD Exacerbation

United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation

Pulmonary Disease, Chronic Obstructive

Canada, Denmark
Novartis Pharmaceuticals

Completed

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

Chronic Obstructive Pulmonary Disease, COPD

Poland, United States
GSNOR Therapeutics, Inc.

Unknown

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)
Wim Janssens
Pro-Active Medical Pty Ltd

Completed

BACE Trial Substudy 1 - PROactive Substudy (PROactive)

Chronic Obstructive Pulmonary Disease

Belgium
Wim Janssens

Completed

BACE Trial Substudy 2 - FarmEc Substudy (FarmEc)

Chronic Obstructive Pulmonary Disease

Belgium
Henan University of Traditional Chinese Medicine
Jiangsu Province Hospital of Traditional Chinese Medicine

Unknown

Bufei Jianpi Granule for Delaying Pulmonary Function Decline in Early-Stage COPD

Chronic Obstructive Pulmonary Disease

China
Henan University of Traditional Chinese Medicine
ShuGuang Hospital

Unknown

Bufei Yishen Granule for Reducing Acute Exacerbation in GOLD Stage 3 or 4 COPD

Chronic Obstructive Pulmonary Disease

China
Wim Janssens
Agentschap voor Innovatie door Wetenschap en Technologie

Terminated

Azithromycin for Acute Exacerbations Requiring Hospitalization (BACE)

Chronic Obstructive Pulmonary Disease

Belgium
Novartis Pharmaceuticals

Completed

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Sweden, Denmark, Norway
GlaxoSmithKline

Completed

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (COPD nDPI)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Slovakia
GlaxoSmithKline

Completed

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Estonia, Ukraine, Korea, Republic of, Norway, Czechia
GlaxoSmithKline

Completed

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD) (AC4115321)

Pulmonary Disease, Chronic Obstructive

United States
AstraZeneca

Completed

A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Ottawa Hospital Research Institute

Completed

TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial

COPD Exacerbation
Novartis Pharmaceuticals

Completed

Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD. (MOVE)

Chronic Obstructive Pulmonary Disease

Germany
Novartis Pharmaceuticals

Completed

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Chronic Obstructive Pulmonary Disease (COPD)

United States, Poland, Romania, Canada, Philippines, Spain, Ukraine, Vietnam
Eisai Co., Ltd.

Completed

Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study

COPD

Japan
University of Alabama at Birmingham

Completed

A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Novartis Pharmaceuticals

Completed

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Egypt, Hungary, France, Guatemala, Panama, Slovakia, Slovenia
H. Lundbeck A/S

Completed

Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder

Major Depressive Disorder
Boehringer Ingelheim

Completed

A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Spain, Canada, Germany
AstraZeneca

Completed

Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Romania, Ukraine, Denmark, Netherlands, Canada
AstraZeneca

Completed

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Poland, Germany, Philippines, Ukraine, Japan, United States, Australia, Canada, Slovakia, Taiwan, Russian Federation
AstraZeneca

Completed

Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol

Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Czech Republic, Poland, Hungary, Romania, Slovakia
Spanish Research Center for Respiratory Diseases

Unknown

Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease (REVASC)

Chronic Obstructive Pulmonary Disease

Spain
AstraZeneca

Completed

A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Germany, Denmark, Italy, Canada, Czech Republic, Hungary, India, Slovakia, France, Colombia, Finland, Taiwan, Iceland, Peru
Novartis

Completed

A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Spain, Germany, South Africa, Australia, Poland, New Zealand, Netherlands
AstraZeneca
Quintiles, Inc.

Terminated

A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United Kingdom
Federal University of São Paulo

Completed

Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients

Pulmonary Disease, Chronic Obstructive | Pulmonary Emphysema | Chronic Bronchitis

Brazil
McMaster University
Boehringer Ingelheim

Completed

Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise

COPD
Hanlim Pharm. Co., Ltd.

Recruiting

Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Korea, Republic of
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects

Chronic Obstructive Pulmonary Disease

China
Western Norway University of Applied Sciences

Recruiting

Digital Follow-up Program for People With Chronic Obstructive Pulmonary Disease in Primary Healthcare

COPD Chronic Obstructive Pulmonary Disease

Norway
JHSPH Center for Clinical Trials
National Heart, Lung, and Blood Institute (NHLBI)

Not yet recruiting

Multi-Center Clean Air Randomized Controlled Trial in COPD (Clean Air)

Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Recruiting

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

Healthy Participants

United States
National Taipei University of Nursing and Health...
Chinese University of Hong Kong

Not yet recruiting

Decision Support on End-of-life Care Planning in Older Adults

Chronic Obstructive Pulmonary Disease
Josefin Eklöf

Recruiting

Live Vaccines and Innate Immune Training in COPD. (COPD-LIVE)

COPD | Trained Innate Immunity

Denmark
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD (AERIFY-4)

Chronic Obstructive Pulmonary Disease

United States, China, Hungary, Israel, Poland, Taiwan, Canada, Chile, Korea, Republic of, Japan
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

China
ReAlta Life Sciences, Inc.

Recruiting

Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Acute Exacerbation of Chronic Obstructive Pulmonary Disease

United States

3

Subscribe